论文部分内容阅读
目的：研究抑癌基因P16与卵巢癌的关系，方法：用免疫组织化学及原位杂交方法检测T72例卵巢肿瘤组织中P16抑癌基因蛋白及其mRNA的表达情况。结果：免疫组化显示：P16在卵巢癌、良性卵巢肿瘤、交界性肿瘤及正常卵巢组织中的检出率分别为：7．89％、60．00％、6．67％和83．30％，各组与卵巢癌组相比有显著差异（P＜0．01）。原位杂交表明在上述不同组织中P16mRNA的阳性率分别为21．05％、70．00％、58．33％和75．00％，各组与卵巢癌组相比有显著差异（P＜0．05）。结论：P16在卵巢癌中的表达明显低于其它卵巢肿瘤及正常卵巢组织中，表明P16作为一种重要的抑癌基因，它的突变与缺失可能与卵巢癌的发生发展密切相关
Objective: To study the relationship between the tumor suppressor gene P16 and ovarian cancer. Methods: Immunohistochemistry and in situ hybridization were used to detect the expression of P16 tumor suppressor gene and its mRNA in T72 ovarian tumor tissues. Results: Immunohistochemistry showed that the positive rates of P16 in ovarian cancer, benign ovarian tumor, borderline tumor and normal ovarian tissue were 7.89%, 60.00%, 6.67% and 83.30%, respectively There was significant difference between each group and ovarian cancer group (P <0.01). In situ hybridization showed that the positive rates of P16 mRNA in the above tissues were 21.05%, 70.00%, 58.33% and 75.00% respectively, there was significant difference between each group and ovarian cancer group (P <0 .05). Conclusion: The expression of P16 in ovarian cancer is significantly lower than that in other ovarian tumors and normal ovarian tissues, indicating that P16 is an important tumor suppressor gene whose mutation and deletion may be closely related to the occurrence and development of ovarian cancer